http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103304440-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33a62710796e131599043055d399597f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-235 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C241-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C243-22 |
| filingDate | 2012-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36e5bdcf450e07146dffbb8d84dfe65a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32c88f8b712efe7a41dd177540698600 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80efc0b9e6e48874d90b66917ac4a46a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4e0ea7052834950294bca510ff90773 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa7732866a87acd071965618b8b5929d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e557d86e2f431d0b9820e4de4c87e7cd |
| publicationDate | 2015-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103304440-B |
| titleOfInvention | 3-[2-(aryl propylenine)hydrazino]-ethyl benzoate compound and application thereof |
| abstract | The invention relates to a 3-[2-(aryl propylenine)hydrazino]-ethyl benzoate compound and an application thereof. The 3-[2-(aryl propylenine)hydrazino]-ethyl benzoate compound is a compound as shown in the formula I or a pharmaceutically acceptable salt (refer to the claim 1 for the specific structure). The compound provided by the invention has strong inhibitory activity on the close related protein-protein interaction in a human immunodeficiency virus gene integration process, namely the human immunodeficiency virus (HIV)-1 integrase and lens epithelium derived growth factor (LEDGF)/p75 interaction. The result proves that the compound provided by the invention is hopefully developed to be a novel target anti-acquired immune deficiency syndrome pharmaceutical for the protein-protein interaction. |
| priorityDate | 2012-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.